What Sets SciClone's FCPA Derivative Suit Apart
On Oct. 3, 2011, SciClone Pharmaceuticals Inc., a California specialty pharmaceutical company with substantial commercial business in China, entered into a stipulation of settlement in connection with several consolidated derivative lawsuits...To view the full article, register now.
Already a subscriber? Click here to view full article